Temozolomide is an oral chemotherapy medicine classified as an alkylating agent. It is widely used in neuro-oncology for the treatment of certain primary brain tumors, particularly high-grade gliomas. Temozolomide is valued for its ability to cross the blood–brain barrier, allowing it to act directly on tumor cells within the central nervous system.

It is prescribed globally as part of standard treatment protocols and is available in both branded and generic formulations.

How Temozolomide Works (Mechanism of Action)

Temozolomide works by damaging the DNA of rapidly dividing cancer cells.

After oral administration, temozolomide is converted in the body to its active metabolite, which:

• Adds methyl groups to tumor cell DNA

• Disrupts DNA replication and repair

• Triggers cancer cell death (apoptosis)

Because brain tumor cells divide rapidly and often have impaired DNA repair mechanisms, they are particularly sensitive to temozolomide’s action.

Approved Uses & Indications

Temozolomide is primarily used in the treatment of malignant brain tumors, including:

• Glioblastoma multiforme (GBM) – newly diagnosed and recurrent

• Anaplastic astrocytoma

• High-grade gliomas

• Recurrent or progressive brain tumors after radiation therapy

In clinical practice, temozolomide is commonly used:

• Alongside radiotherapy (concurrent phase)

• As maintenance therapy following radiation

Dosage & Administration

Important: Dosage is individualized and must be determined by an oncologist.

General administration principles:

• Administered orally, usually once daily

• Taken on an empty stomach to reduce nausea

• Given in treatment cycles (e.g., 5 days on, 23 days off)

Typical use patterns include:

• Daily low-dose therapy during radiotherapy

• Higher-dose cycles during maintenance therapy

Blood counts and organ function are closely monitored throughout treatment.

Common Side Effects

Like most chemotherapy agents, temozolomide may cause side effects that vary in severity.

Common Side Effects

• Nausea and vomiting

• Fatigue

• Loss of appetite

• Constipation

• Headache

• Hair thinning or hair loss

Serious or Less Common Side Effects

• Low white blood cell count (neutropenia)

• Low platelet count (thrombocytopenia)

• Increased risk of infections

• Liver enzyme abnormalities

• Rare cases of secondary blood disorders

Prompt reporting of fever, unusual bleeding, or severe fatigue is essential.

Precautions, Warnings & Contraindications

Special caution is required in the following situations:

• Pregnancy: Temozolomide may cause fetal harm; effective contraception is required

• Breastfeeding: Not recommended during treatment

• Bone marrow suppression: Regular blood count monitoring is mandatory

• Liver or kidney impairment: Dose adjustments may be needed

• Infection risk: Patients may require preventive medications during prolonged therapy

Drug interactions should be reviewed carefully before starting treatment.

Available Formulations

Temozolomide is available in multiple strengths and capsule forms.

Common dosage strengths include:

• 5 mg

• 20 mg

• 100 mg

• 140 mg

• 180 mg

• 250 mg capsules

Both innovator brands and generic versions are widely manufactured and used in oncology centers worldwide.

Generic Availability & Alternatives

Generic temozolomide is widely available and considered therapeutically equivalent to branded versions when sourced from reputable manufacturers.

Depending on tumor type and treatment stage, alternatives or adjunct therapies may include:

• Other alkylating agents

• Targeted therapies

• Tumor-treating fields

• Clinical trial medications

Treatment decisions are based on tumor genetics, patient condition, and response to prior therapy.

Storage & Handling Information

• Store at room temperature (as specified on packaging)

• Protect from moisture and light

• Capsules should not be opened or crushed

• Caregivers should avoid direct contact with capsule contents

Temozolomide is considered a cytotoxic drug and should be handled with appropriate precautions.